Full Text
EE42 Economic Evaluation of Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in Japan

Abstract

Authors

T. Tsuyuki K. Morimoto T. Maeda W. Chen K. Moriwaki K. Shimozuma

Back to Volume 26, Supplemental Issue 6S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×